ReviewCurrent treatment options in oncology2022
Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light.
Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors.Investigational new drugs · 2025Trial
- Global research trends in fecal microbiota transplantation combined with immune checkpoint inhibitors for cancer immunotherapy: a bibliometric analysis.Translational cancer research · 2026Article
- [Fecal microbiota transplantation inhibits colonic tumor growth in mice by suppressing the TLR4/MyD88/NF-κB signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities.Cancers · 2026Review
- Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines.Clinical and experimental medicine · 2026Review
- Targeting microbiome-driven epigenetic modifications: a new frontier in breast cancer treatment.Clinical epigenetics · 2026Review
- Gastric bacterial microbiota and gastric carcinogenesis: from dysbiosis to immune remodeling and therapeutic opportunities.Frontiers in immunology · 2026Review
- Role of Gut Microbiome in Oncogenesis and Oncotherapies.Cancers · 2025Review
- The emerging role of the gut microbiota in vaccination responses.Gut microbes · 2025Review
- From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.Gut microbes · 2025Review
- Targeting Gut-Lung Crosstalk in Acute Respiratory Distress Syndrome: Exploring the Therapeutic Potential of Fecal Microbiota Transplantation.Pathogens (Basel, Switzerland) · 2025Review
- Review
- Bibliometric analysis of global research trends in delivery systems for breast cancer immunotherapy.Discover oncology · 2025Article
- Fecal Microbiota Transplantation Alleviates Airway Inflammation in Asthmatic Rats by Increasing the Level of Short-Chain Fatty Acids in the Intestine.Inflammation · 2025Article
- Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome.Journal of clinical medicine · 2025Review
- Research progress on fecal microbiota transplantation in tumor prevention and treatment.Open life sciences · 2025Review
- Gut microbiome and lung cancer: mechanisms, interactions, and dietary interventions.Gut microbes reports · 2025Review
- Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors.Cancers · 2024Review
- The bacterial microbiome and cancer: development, diagnosis, treatment, and future directions.Clinical and experimental medicine · 2024Review
- Fecal Microbiota Transplantation: Insights into Colon Carcinogenesis and Immune Regulation.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementImmunotherapy is revolutionizing tumor treatment by activating the immune response to tumors. Among them, immunotherapy represented by immune checkpoint inhibitors is considered to be a milestone in tumor treatment. It has revolutionized the management of advanced malignant tumors by activating T cells, promoting cytotoxic signaling pathways, and killing tumor cells, effectively improving the overall survival of patients. However, resistance to immunotherapy and immune-related adverse events remain challenges for immunotherapy. It has been demonstrated in previous studies that modulating intestinal microbiota can enhance immunotherapy response and reduce complications. Currently, the more mature method for microbiota regulation is fecal microbiota transplantation, which involves transfering a donor's microbiome to the recipient in the form of capsules or fecal microbiota suspension to restore the richness of the recipient's intestinal microbiota. In terms of cancer immunotherapy, fecal microbiota transplantation in patients who fail to respond to immune checkpoint inhibitors is expected to produce better prognosis for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.